I feel that just based on the upper end of Livent's 2022 Full...

I feel that just based on the upper end of Livent's 2022 Full year Guidance , they're SP would be looking to double by moving to US$40 .........or even potentially US$50 per share within 9 months or so.

So that would be somewhere's around US$16 -US $20 Billion in Market Cap within a years time and paving the way and supporting a strong argument for a doubling in Sayona's Market Cap based on everything it has going on with its own projects to around $4 - $4.5 Billion.

They obviously have a lot of work to do and always have this ' Excluding Nemaska ' disclaimer slapped on any of the limited commentary on Quebec Hydroxide developments.

Having said that , I still find it interesting that they have agreed to move to 50% holding of this project for what amounts to 5 times their entry price for their first 25% stake and taking their investment in Nemaska to over C$400 million or 4 times that of what Sayona paid for even NAL.

You would think that Whabouchi must be getting close to at least producing it nameplate spodumene product on this basis.

Anyway , their Quebec operations still very much cloaked in ' silent ' secrecy really.

But at least we have some comparative numbers we can wrap around the Nemaska operation versus the ' Multi ' project operation of Sayona.